Our data indicate that PD‐L2 level allows differentiating the COVID‐ILD patients mainly into two groups post‐COVID‐19: those patients who increased the PD‐L2 level (concerning their acute COVID‐19 level) and still display lung alterations and those who decreased, suggesting that PD‐L2 level can be used to determine if COVID‐ILD patients will maintain for long time lung alterations. Here, PDCD1LG2 is linked to COVID-19.